IPM chemotherapy in cytokine refractory renal cell cancer
Author:
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Link
http://www.nature.com/articles/6600934.pdf
Reference18 articles.
1. Allen MJ, Vaughan M, Webb A, Johnston S, Savage P, Eisen T, Bate S, Moore J, Ahern R, Gore ME (2000) Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 83: 980–985
2. Anonymous (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators [see comments]. Lancet 353: 14–17
3. Atzpodien J, Illiger HJ, Metzner B, Ukena D, Schott H, Funke PJ, Gramatzki M, Jurgenson S, Wandert T, Patzelt T, Reitz M (2001) IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trials. Br J Cancer 8: 1130–1136
4. Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I (1999) Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer. J Clin Oncol 17: 319–323
5. Childs R, Chernoff A, Contentin N (2000) Regression of metastatic renal cell carcinoma after nonmyeloablative allogenic peripheral blood stem cell transplantation. N Engl J Med 343: 750–758
Cited by 20 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma;Translational Cancer Research;2024-05
2. Underlying mechanisms of novel cuproptosis-related dihydrolipoamide branched-chain transacylase E2 (DBT) signature in sunitinib-resistant clear-cell renal cell carcinoma;Aging;2024-02-01
3. Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma;Journal of Kidney Cancer and VHL;2022-09-29
4. Suppression of homology-dependent DNA double-strand break repair induces PARP inhibitor sensitivity in VHL-deficient human renal cell carcinoma;Oncotarget;2017-12-19
5. Follow-up After Treatment for Renal Cell Carcinoma: The Evidence Beyond the Guidelines;European Urology Focus;2016-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3